Loading the company…
Loading the company…
Families: Bronchoscopy & lung nodule, Colonoscopy & upper endoscopy.
All companies · Product and company coverage
In the last ten years FDA made 2 decisions for Fujifilm Healthcare (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2024 (1). The latest was on 2024-02-07.
| Family | Decisions on record |
|---|---|
| Bronchoscopy & lung nodule | 1 |
| Colonoscopy & upper endoscopy | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2024-02-07 | 510(k) | K240075 | FUJIFILM Endoscope Model EB-710XT |
| 2023-09-01 | 510(k) | K232314 | Hood (DH-106STL, DH-116STL, DH-126STL, DH-096ST) |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Fujifilm Healthcare.
In 2025, Fujifilm Healthcare reported engagement with 535 surgeons and other clinicians in the states MedaRep covers, worth $352K in consulting, speaking, meals and travel for its device products, the most in Pennsylvania ($127K to 23). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Pennsylvania ($127K, 23 engaged), California ($35K, 75 engaged), Illinois ($29K, 20 engaged), New York ($29K, 45 engaged), Texas ($22K, 72 engaged).